Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

2.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

500
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
500
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

525
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
525
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A nurse-coordinated intervention programme vs standard of care after an acute coronary syndrome: the ALLEPRE trial.

European heart journal·2026
Same author

[Fast-track model for the management of patients with non-ST-elevation acute coronary syndrome. Hub-Spoke experience in Umbria].

Giornale italiano di cardiologia (2006)·2026
Same author

Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial.

Revista espanola de cardiologia (English ed.)·2026
Same author

Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis.

Circulation·2026
Same author

Genetic predisposition to elevated lipoprotein(a) in early-onset myocardial infarction.

European journal of preventive cardiology·2026
Same author

Effect of beta blockers in acute and chronic coronary syndromes without reduced ejection fraction: a landmark analysis from the REBOOT trial.

European heart journal. Cardiovascular pharmacotherapy·2026

相关实验视频

Updated: May 5, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

14.4K

在没有ST段升高的急性冠状动脉综合征中,Abciximab对前列红蛋白激活和血栓生成的影响:全球利用在急性冠状动脉综合征中打开封闭冠状动脉的策略试验IV (GUSTO IV ACS) 意大利血液学子研究

Piera Angelica Merlini1, Alessandra Repetto, Alessandro Lombardi

  • 1Division of Cardiology, Ospedale Niguarda, Milan, Italy. ardis001@planet.it.

Circulation
|February 28, 2002
PubMed
概括

在患有急性冠状动脉综合征的患者中,abciximab没有降低血栓生成标志物. 这项研究发现,随着abciximab治疗,前激素激活或血栓生成没有减少.

更多相关视频

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.0K

相关实验视频

Last Updated: May 5, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

14.4K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.0K

科学领域:

  • 心脏病学 心脏病学
  • 血液学 血液学 血液学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 在干预手术过程中,abciximab通过阻断血小板糖蛋白IIb/IIIa受体,有效地减少心脏事件.
  • 新出现的证据表明abciximab可能具有直接的抗血作用.
  • 关于abciximab对非ST升高急性冠状动脉综合征中的体内血栓生成标记物的影响的数据有限.

研究的目的:

  • 调查abciximab对急性冠状动脉综合征患者在没有ST升高的情况下激活前激素和产生血栓的作用.
  • 评估abciximab是否会影响这种患者群体中的凝血级联的体内标记物.

主要方法:

  • 167名患有急性冠状动脉综合征而没有ST升高的患者随机分组接受abciximab (24或48小时) 或安慰剂,除了肝素.
  • 血中1+2原蛋白片段和氨酸/抗氨酸复合物的度在基线,24小时,48小时和1个月内被测量.
  • 进行了统计分析,以比较治疗组之间的标记物变化.

主要成果:

  • 在48小时和1个月后,所有组 (安慰剂,24小时的abciximab,48小时的abciximab) 中,前热血素片段1+2水平显著增加.
  • 在整个研究期间,所有组的血血/抗血复合物水平在所有组中保持相似.
  • 在abciximab和安慰剂组之间没有观察到血栓生成标志物的显著差异.

结论:

  • 在没有ST升高的急性冠状动脉综合征患者中,Abciximab似乎不会降低前列红素激活.
  • 该研究没有发现任何证据表明abciximab在这个患者队列中减少了血栓生成.
  • 这些发现表明abciximab在ACS中的抗血栓作用可能不涉及直接调节前列血激活或血生成.